67Cu-SARbisPSMA)) is a new PSMA targeting drug labeled with 67Cu and developed by the Australian company Clarity Pharmaceuticals as therapeutic analogue of 64Cu-SARbisPSMA. The first US Phase I/II clinical trial involving both 64Cu/67Cu-SARbisPSMA Phase I/II trial is expected to start inclusion before end of the year 2021
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.